US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion Daily S&P Biotech Bull 3x Shares

250.41

+0.01000.00%

Post-market: 251.771.36+0.54%19:49 EDT

Volume:216.45K

Turnover:54.77M

Market Cap:494.43M

PE:- -

High:259.83

Open:253.12

Low:242.96

Close:250.40

52wk High:341.93

52wk Low:76.29

Shares:1.97M

Float Shares:1.97M

Volume Ratio:0.83

T/O Rate:10.96%

Dividend:1.00

Dividend Rate:0.40%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Biofrontera announces FDA approval of Ameluz supplemental new drug application

Sector Update: Healthcare Stocks Rise Premarket Monday

MT Newswires Live

Beta Bionics Lowers 2026 Revenue Guidance, Receives FDA Clearance for Mint Patch Pump

MT Newswires Live

Telix Pharmaceuticals ADRs Gain on FDA Approval for Brain Cancer Imaging Drug

Tenaya Therapeutics granted RMAT designation from FDA for TN-401

Nasus Pharma Wins FDA Clearance to Begin NS002 Anaphylaxis Trial

Armata Pharma Shares Rise on FDA Breakthrough Therapy Designation for Antibacterial Treatment

Scholar Rock Wins FDA Approval for SMA Therapy

Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis

TuHURA Biosciences: FDA clears IND for TBS-2025 VISTA-inhibiting antibody

Scholar Rock price target raised to $84 from $76 at BMO Capital

Organon announces U.S. FDA accepted for review Sebela’s sNDA for Miudella

Dr. Reddy’s Reports FDA Records Assessment at Mexican API Plant Concluding with Two Observations

Max Healthcare to Engage Investors at J.P. Morgan India Conference 2026

FDA Allows Hisun Pharmaceutical's Glucosamine Hydrochloride in US Market

MT Newswires Live

Doximity’s Underappreciated AI Ecosystem and Health-System Traction Support Unchanged $35 Buy Target

Takeda announces FDA acceptance of zasocitinib under priority review

UMP Healthcare Sets Board Meeting to Approve 2026 Annual Results and Consider Dividend

Apeloa Pharma's Subsidiary Secures FDA Nod for Brivaracetam Tablets

U.S. FDA Grants Priority Review to Takeda Pharmaceutical's Zasocitinib NDA for Plaque Psoriasis

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/stock/LABU/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"Direxion Daily S&P Biotech Bull 3x Shares","latestPrice":250.41,"timestamp":1789588800000,"preClose":250.4,"halted":0,"volume":216452,"hourTrading":{"tag":"盘后","latestPrice":251.772,"preClose":250.41,"latestTime":"19:49 EDT","volume":1014,"amount":254252.08380000002,"timestamp":1789602584431,"change":1.362,"changeRate":0.005439,"amplitude":0.006869},"delay":0,"changeRate":0.000039936102236385406,"floatShares":1974486,"shares":1974486,"eps":0,"marketStatus":"Post-Mkt","change":0.01,"latestTime":"09-16 19:56:32 EDT","open":253.12,"high":259.83,"low":242.96,"amount":54769364.71576,"amplitude":0.067372,"askPrice":255.2,"askSize":200,"bidPrice":250.8,"bidSize":200,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789603200000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":250.4,"sharesOutstanding":3074486,"nav":268.659,"aum":530464172.89,"dividendRate":0.004,"bidAskSpread":0.003539,"preHourTrading":{"tag":"盘前","latestPrice":254.8128,"preClose":250.4,"latestTime":"09:28 EDT","volume":4289,"amount":1082884.5326099999,"timestamp":1789565312693,"change":4.4128,"changeRate":0.017623,"amplitude":0.012511},"postHourTrading":{"tag":"盘后","latestPrice":251.772,"preClose":250.41,"latestTime":"19:49 EDT","volume":1014,"amount":254252.08380000002,"timestamp":1789602584431,"change":1.362,"changeRate":0.005439,"amplitude":0.006869},"volumeRatio":0.828297,"impliedVol":0.9487,"impliedVolPercentile":0.6773},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1974486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.828297,"shares":1974486,"dividePrice":1.0016,"high":259.83,"amplitude":0.067372,"preClose":250.4,"low":242.96,"week52Low":76.29,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":250.41,"eps":0,"divideRate":0.004,"volume":216452,"delay":0,"ttmEps":0,"open":253.12,"prevYearClose":159.39,"prevWeekClose":261.3,"prevMonthClose":296.31,"prevQuarterClose":292.1,"fiveDayClose":279.02,"twentyDayClose":289.98,"sixtyDayClose":230.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2667661630","title":"Biofrontera announces FDA approval of Ameluz supplemental new drug application","url":"https://stock-news.laohu8.com/highlight/detail?id=2667661630","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667661630?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:35","pubTimestamp":1789392922,"startTime":"0","endTime":"0","summary":"Biofrontera (BFRI) announced that the FDA has approved the company’s supplemental new drug application, or sNDA, for Ameluz topical gel, 10%, in co...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biofrontera-announces-fda-approval-of-ameluz-supplemental-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biofrontera-announces-fda-approval-of-ameluz-supplemental-new-drug-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","MRNY","IEIH","LABU","GNMX","TECB","IYH","GDOC","BK4007","PSCH","PINK","SYNB","BFRI","NVIB","LFSC","BMED","TBXU","IDNA","BK4585","BBP","MRNX","XLVX","RSPH","BK4588","FRTY","IBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667970669","title":"Sector Update: Healthcare Stocks Rise Premarket Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2667970669","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667970669?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:17","pubTimestamp":1789391865,"startTime":"0","endTime":"0","summary":"Healthcare stocks were rising premarket Monday, with the State Street Health Care Select Sector SPDR ETF  advancing by 1.2% and the iShares Biotechnology ETF  0.3% higher.GSK  licensor Hansoh Pharmaceutical reported that a phase 3 trial evaluating risvutatug rezetecan, or Ris-Rez, against commonly used topotecan in patients with relapsed small-cell lung cancer met its primary endpoint. GSK stock was up more than 4% pre-bell.Astrazeneca  shares were up more than 2% after the company said a late-stage study of its drug Enhertu showed a six-month improvement in median progression-free survival as a first-line treatment for advanced HER2-mutant non-small cell lung cancer.Johnson & Johnson  stock was up more than 1% after the company said a phase 3 trial of its lung cancer drug Rybrevant combined with chemotherapy resulted in a median overall survival of 34.3 months. Separately, The Wall Street Journal reported that Apollo Global Management  is in talks to acquire Johnson & Johnson's hips-a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GSK.UK","LU1280957306.USD","SGXZ80539844.SGD","IYH","LU0053666078.USD","IE00BSNM7G36.USD","BMED","IBB","LU2213496289.HKD","LU0069063385.USD","LU0210536198.USD","LU0912757837.SGD","APO","PJP","FHLC","AZN","JNJ","LU1228905037.USD","HCSG","LU2750360641.GBP","PRVT","XLV","LU2133065610.SGD","IE00B4R5TH58.HKD","MEDX","LU1043141123.HKD","TRUH","LU1935042991.SGD","AAUM","GSKH","FTXH","GDOC","GSK","LABU","AZNH","IHE","RXL","BK4550","LU0289739699.SGD","VHT","XBI","LU2471134796.USD","GPZ","JDOC","LU0203347892.USD","LU1244550577.SGD","LBO","LU1718418525.SGD","IXJ","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667669396","title":"Beta Bionics Lowers 2026 Revenue Guidance, Receives FDA Clearance for Mint Patch Pump","url":"https://stock-news.laohu8.com/highlight/detail?id=2667669396","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667669396?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:04","pubTimestamp":1789391052,"startTime":"0","endTime":"0","summary":"Beta Bionics (BBNX) said Monday it expects 2026 revenue of about $121 million to $126 million, down from its previous guidance of $131 million to $136 million.Analysts polled by FactSet expect $132.5 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BBNX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667669394","title":"Telix Pharmaceuticals ADRs Gain on FDA Approval for Brain Cancer Imaging Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2667669394","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667669394?lang=en_us&edition=fundamental","pubTime":"2026-09-14 21:03","pubTimestamp":1789390980,"startTime":"0","endTime":"0","summary":"American depositary receipts of Telix Pharmaceuticals Limited rose after the Food and Drug Administration approved the company's new drug application for Pixclara, a drug used in brain cancer imaging.ADRs rose 7.9% to $12.18 in premarket trading on Monday. As of Friday's market close, ADRs were up 51% year to date.Pixclara is a radioactive diagnostic drug indicated for use with positron emission tomography to differentiate recurrent or progressive gliomas from changes related to treatment.Gliomas are the most common form of central nervous system cancer, accounting for about 30% of all brain and CNS tumors and 80% of all malignant brain tumors, the company said.Pixclara is now the first FDA-approved positron emission tomography imaging drug for glioma, the company said.\"Pixclara will provide physicians in the U.S. with more certainty in their diagnoses and greater confidence in their treatment planning for patients,\" Telix's Chief Executive Kevin Richardson said.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","TLX","BK4139","LABU","SCHY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667808669","title":"Tenaya Therapeutics granted RMAT designation from FDA for TN-401","url":"https://stock-news.laohu8.com/highlight/detail?id=2667808669","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667808669?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:55","pubTimestamp":1789390517,"startTime":"0","endTime":"0","summary":"Tenaya Therapeutics (TNYA) announced that the FDA has granted Regenerative Medicine Advanced Therapy, or RMAT, designation to TN-401, Tenaya’s gene...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tenaya-therapeutics-granted-rmat-designation-from-fda-for-tn-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tenaya-therapeutics-granted-rmat-designation-from-fda-for-tn-401-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LABU","BK4585","TNYA","BK4588","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667698696","title":"Nasus Pharma Wins FDA Clearance to Begin NS002 Anaphylaxis Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2667698696","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667698696?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:47","pubTimestamp":1789390067,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd. ( ($NSRX) ) has shared an announcement. On September 14, 2026, Nasus Pharma announced that the U.S. Food and Drug Administration ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-wins-fda-clearance-to-begin-ns002-anaphylaxis-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nasus-pharma-wins-fda-clearance-to-begin-ns002-anaphylaxis-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX","LABU","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667666190","title":"Armata Pharma Shares Rise on FDA Breakthrough Therapy Designation for Antibacterial Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2667666190","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667666190?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:47","pubTimestamp":1789390020,"startTime":"0","endTime":"0","summary":"Shares of Armata Pharmaceuticals rose after the company got breakthrough therapy designation from the Food and Drug Administration for a potential antibacterial treatment.The stock gained 10% to $5.92 in premarket trading on Monday. As of Friday's market close, shares were down 14% year to date.The breakthrough designation expedites the review of medicines that treat serious or life-threatening conditions, and that have shown the potential for substantial improvement over available therapies based on preliminary clinical evidence.Armata said it got the designation for AP-SA02, its intravenously-administered product candidate for adjunct treatment of complicated bacteremia caused by methicillin-sensitive staphylococcus aureus or methicillin-resistant S. aureus.Complicated S. aureus bacteremia is a serious bloodstream infection associated with significant relapse rate, morbidity and mortality, the company said.The company said it plans to work closely with the FDA to efficiently advance ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARMP","LABU","BK4585","BK4139","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667066661","title":"Scholar Rock Wins FDA Approval for SMA Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2667066661","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667066661?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:32","pubTimestamp":1789389127,"startTime":"0","endTime":"0","summary":"The latest update is out from Scholar Rock Holding ( ($SRRK) ). On September 11, 2026, Scholar Rock announced U.S. FDA approval of ISEMBYLD (apiteg...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/scholar-rock-wins-fda-approval-for-sma-therapy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","MRNY","LFSC","LABU","PSCH","NVIB","IEIH","MRNX","XLVX","BBP","BK4585","GNMX","PINK","GDOC","SYNB","IBB","RSPH","IDNA","TBXU","TECB","IYH","BK4588","MEDI","FRTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667665532","title":"Nasus Pharma Announces FDA Clearance to Initiate Clinical Study of NS002 in the Treatment of Anaphylaxis","url":"https://stock-news.laohu8.com/highlight/detail?id=2667665532","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667665532?lang=en_us&edition=fundamental","pubTime":"2026-09-14 20:00","pubTimestamp":1789387200,"startTime":"0","endTime":"0","summary":"Clinical study to evaluate NS002, the Company's investigational intranasal epinephrine powder, as a needle-free alternative to EpiPen for patients experiencing anaphylaxis and will compare self-admini","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/14/3361032/0/en/nasus-pharma-announces-fda-clearance-to-initiate-clinical-study-of-ns002-in-the-treatment-of-anaphylaxis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4585","BK4588","LABU","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667665822","title":"TuHURA Biosciences: FDA clears IND for TBS-2025 VISTA-inhibiting antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=2667665822","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667665822?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:50","pubTimestamp":1789386637,"startTime":"0","endTime":"0","summary":"TuHURA Biosciences (HURA) announced that the U.S. FDA has given clearance to TuHURA’s Investigational New Drug application for its TBS-2025 VISTA-i...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-fda-clears-ind-for-tbs-2025-vista-inhibiting-antibody-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/tuhura-biosciences-fda-clears-ind-for-tbs-2025-vista-inhibiting-antibody-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4139","BK4585","HURA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667134663","title":"Scholar Rock price target raised to $84 from $76 at BMO Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2667134663","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667134663?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:36","pubTimestamp":1789385772,"startTime":"0","endTime":"0","summary":"BMO Capital raised the firm’s price target on Scholar Rock (SRRK) to $84 from $76 and keeps an Outperform rating on the shares. The FDA approval of...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/scholar-rock-price-target-raised-to-84-from-76-at-bmo-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IBB","SRRK","LFSC","GDOC","GNMX","IBRN","XLVX","FRTY","IDNA","LABU","MEDI","BK4139","THNR","NVIB","MRNX","TBXU","BK4585","IYH","PINK","SYNB","RSPH","BMED","BBP","MRNY","PSCH","IEIH","TECB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667631396","title":"Organon announces U.S. FDA accepted for review Sebela’s sNDA for Miudella","url":"https://stock-news.laohu8.com/highlight/detail?id=2667631396","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667631396?lang=en_us&edition=fundamental","pubTime":"2026-09-14 19:36","pubTimestamp":1789385762,"startTime":"0","endTime":"0","summary":"Organon (OGN) announced the US Food and Drug Administration, FDA, has accepted for review Sebela Women’s Health’s supplemental New Drug Application...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/organon-announces-u-s-fda-accepted-for-review-sebelas-snda-for-miudella-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/organon-announces-u-s-fda-accepted-for-review-sebelas-snda-for-miudella-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065171311.SGD","OGN","BK4559","FXH","LU2065170008.USD","LABU","BK4588","BK4585","LU2065171402.SGD","BK4007","LU2065169927.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667500216","title":"Dr. Reddy’s Reports FDA Records Assessment at Mexican API Plant Concluding with Two Observations","url":"https://stock-news.laohu8.com/highlight/detail?id=2667500216","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667500216?lang=en_us&edition=fundamental","pubTime":"2026-09-14 18:58","pubTimestamp":1789383525,"startTime":"0","endTime":"0","summary":"An announcement from Dr Reddy’s Laboratories ( ($RDY) ) is now available. Dr. Reddy’s Laboratories disclosed that the U.S. Food and Drug Administra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/dr-reddys-reports-fda-records-assessment-at-mexican-api-plant-concluding-with-two-observations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/dr-reddys-reports-fda-records-assessment-at-mexican-api-plant-concluding-with-two-observations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667065004","title":"Max Healthcare to Engage Investors at J.P. Morgan India Conference 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2667065004","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667065004?lang=en_us&edition=fundamental","pubTime":"2026-09-14 18:53","pubTimestamp":1789383237,"startTime":"0","endTime":"0","summary":"An announcement from Max Healthcare Institute Ltd ( ($IN:MAXHEALTH) ) is now available. Max Healthcare Institute Ltd, one of India’s leading listed...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/max-healthcare-to-engage-investors-at-j-p-morgan-india-conference-2026?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/max-healthcare-to-engage-investors-at-j-p-morgan-india-conference-2026?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1074936037.SGD","XBI","LU1791710582.SGD","LU1244550221.USD","BK4585","BK4211","HCSG","LU0225283273.USD","LU0795875086.SGD","LU1244550494.USD","LU1363072403.SGD","LU0128526141.USD","LU2264538146.SGD","XLV","LABU","IE00B3S45H60.SGD","LU0053666078.USD","LU0912757837.SGD","LU1989772840.SGD","LU0390134368.USD","LU0882574139.USD","LU0210528500.USD","LU0106261372.USD","IE00BZ1G4Q59.USD","KBWB","LU1732800096.USD","MNDmain","LU2357305700.SGD","IE00BKVL7J92.USD","LU2133065610.SGD","LU1720051017.SGD","LU0314104364.USD","LU0528227936.USD","LU2028103732.USD","LU0106831901.USD","IE00B775SV38.USD","LU0320765646.SGD","IAI","LU0158827948.USD","LU1989772923.USD","LU0234570918.USD","BK4127","LU0557290698.USD","LU1791710400.SGD","BK4504","BK4137","LU1668664300.SGD","LU0795875169.SGD","LU0029874061.USD","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667657006","title":"FDA Allows Hisun Pharmaceutical's Glucosamine Hydrochloride in US Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2667657006","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667657006?lang=en_us&edition=fundamental","pubTime":"2026-09-14 18:38","pubTimestamp":1789382283,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration recognized Zhejiang Hisun Pharmaceutical's  glucosamine hydrochloride product as safe, according to a Saturday filing with the Shanghai bourse.The product, manufactured by subsidiary Zhejiang Yunsheng Synthetic Biology, will be allowed for marketing in the U.S. and can be sold as a safe dietary ingredient, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","600267","BK0028","BK4585","BK0239","BK0188","LABU","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667652037","title":"Doximity’s Underappreciated AI Ecosystem and Health-System Traction Support Unchanged $35 Buy Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2667652037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667652037?lang=en_us&edition=fundamental","pubTime":"2026-09-14 17:56","pubTimestamp":1789379769,"startTime":"0","endTime":"0","summary":"Doximity, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Craig Hettenbach from Morgan Stanley maintained a Bu...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/doximitys-underappreciated-ai-ecosystem-and-health-system-traction-support-unchanged-35-buy-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/doximitys-underappreciated-ai-ecosystem-and-health-system-traction-support-unchanged-35-buy-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","LU1720051017.SGD","LU0971096721.USD","LU1244550494.USD","LU0528227936.USD","LU1244550577.SGD","IE00BZ1G4Q59.USD","LU0320765646.SGD","IE00BKVL7J92.USD","LU0234570918.USD","LU0053666078.USD","DOCS","LU1064131342.USD","IE00B775SV38.USD","LU1548497426.USD","LU0912757837.SGD","LU0158827948.USD","LABU","LU0098860793.USD","LU1162221912.USD","BK4581","BK4127","LU2347655156.SGD","LU0158827781.USD","XBI","BK4504","LU0106831901.USD","LU0390134368.USD","QTOC","LU2023251221.USD","LU0314104364.USD","LU2089283258.USD","LU1988902786.USD","LU2028103732.USD","LU2111349929.HKD","VTHR","LU1732799900.SGD","IAI","LU1791710582.SGD","BK4539","LU0795875169.SGD","LU0106261372.USD","CHAT","LU0882574139.USD","LU0795875086.SGD","KBWB","XLV","AGIX","AIPO","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667528706","title":"Takeda announces FDA acceptance of zasocitinib under priority review","url":"https://stock-news.laohu8.com/highlight/detail?id=2667528706","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667528706?lang=en_us&edition=fundamental","pubTime":"2026-09-14 17:15","pubTimestamp":1789377307,"startTime":"0","endTime":"0","summary":"Takeda (TAK) announced that the FDA accepted its new drug application, or NDA, under priority review for zasocitinib for the treatment of adults wi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/takeda-announces-fda-acceptance-of-zasocitinib-under-priority-review-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/takeda-announces-fda-acceptance-of-zasocitinib-under-priority-review-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4588","LABU","TAK","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667654572","title":"UMP Healthcare Sets Board Meeting to Approve 2026 Annual Results and Consider Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2667654572","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667654572?lang=en_us&edition=fundamental","pubTime":"2026-09-14 17:09","pubTimestamp":1789376973,"startTime":"0","endTime":"0","summary":"UMP Healthcare Holdings Limited ( ($HK:0722) ) just unveiled an announcement. UMP Healthcare Holdings Limited has scheduled a board meeting for 24 ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ump-healthcare-sets-board-meeting-to-approve-2026-annual-results-and-consider-dividend?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ump-healthcare-sets-board-meeting-to-approve-2026-annual-results-and-consider-dividend?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LU0128526141.USD","BK4137","BK4588","LU0029874061.USD","HCSG","XLV","LABU","BK4581","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123614423","title":"Apeloa Pharma's Subsidiary Secures FDA Nod for Brivaracetam Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1123614423","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123614423?lang=en_us&edition=fundamental","pubTime":"2026-09-14 16:58","pubTimestamp":1789376302,"startTime":"0","endTime":"0","summary":"Apeloa Pharmaceutical Co.,Ltd. (000739.SZ) has announced that its wholly-owned subsidiary, Zhejiang Apeloa Jutai Pharmaceutical Co., Ltd. (\"Jutai Pharma\"), has received notification from the U.S....","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["000739","LABU","BK0060","BK4588","BK0188","BK0239","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667765158","title":"U.S. FDA Grants Priority Review to Takeda Pharmaceutical's Zasocitinib NDA for Plaque Psoriasis","url":"https://stock-news.laohu8.com/highlight/detail?id=2667765158","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667765158?lang=en_us&edition=fundamental","pubTime":"2026-09-14 16:50","pubTimestamp":1789375847,"startTime":"0","endTime":"0","summary":"The U.S. Food and Drug Administration  accepted Takeda Pharmaceutical's  new drug application  for zasocitinib under priority review for adults with moderatetosevere plaque psoriasis, according to a Monday filing with the Japanese bourse.The application is supported by Phase III LATITUDE PsO 3001 and 3002 trials, which met all primary and ranked secondary endpoints. About 70% of patients achieved clear or nearly clear skin by Week 16, with improvements seen from Week 4 and sustained through Week 52, the filing said.Shares of Takeda Pharmaceutical added over 1% at market close.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LABU","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":21,"pageCount":6,"totalSize":412,"code":"91000000","status":"200"}]}}